BioRestorative Therapies Inc BRTX has entered into agreements with Vantage Clinical Trials LLC for its Phase 2 trial targeting chronic lumbar disc disease (cLDD).
Vantage Clinical Trials LLC is located in Florida and brings three separate clinical sites to BioRestortive’s Phase 2 trial.
BioRestorative’s Phase 2 trial is a double-blind controlled, randomized study to evaluate the safety and preliminary efficacy of a single dose intradiscal injection of its autologous investigational stem cell-based therapeutic, BRTX-100.
99 eligible patients will be randomized at up to 15 sites in the U.S. to receive either BRTX-100 or control.
“With the execution of the Vantage agreements, we are bringing on board three additional sites with a well-established history of conducting clinical research,” said Lance Alstodt, Chief Executive Officer of BioRestorative Therapies.
“Adding high-profile sites is our top priority as we ramp up enrollment for our clinical trial targeting cLDD,” he added.
Price Action: BRTX shares closed at $3.10 on Tuesday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.